Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.51 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.50 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.50 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.50 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.47 |
| ▸ | ROS1 | P08922 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10208739 | 0.92 | ZAP70 (0.59) | BRD4MAPK7LRRK2ZAP70ROS1 | |
| SCHEMBL12917680 | 0.91 | LRRK2 (0.52) | BRD4MAPK7LRRK2DCLK1BRDT | |
| SCHEMBL12917681 | 0.85 | LRRK2 (0.55) | LRRK2DCLK1ZAP70TTKROS1 | |
| SCHEMBL12918023 | 0.84 | MAPK7 (0.55) | BRD4MAPK7LRRK2DCLK1BRDT | |
| SCHEMBL12781754 | 0.84 | ALK (0.51) | BRD4ZAP70TTKALKIGF1R | |
| SCHEMBL12780160 | 0.84 | ALK (0.51) | BRD4ZAP70TTKALKIGF1R | |
| SCHEMBL12917662 | 0.83 | LRRK2 (0.64) | LRRK2TTK | |
| SCHEMBL12780185 | 0.82 | LRRK2 (0.57) | LRRK2TTK | |
| SCHEMBL10208085 | 0.82 | LRRK2 (0.62) | BRD4MAPK7LRRK2DCLK1ZAP70 | |
| SCHEMBL12780106 | 0.81 | ZAP70 (0.62) | LRRK2ZAP70ROS1ALKIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | TYMS, TYMP, DPYD | BRD4 1634/4885MAPK7 2137/4885LRRK2 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.